Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01284387 | Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 126 | — | — | Jan 1, 2011 | Feb 1, 2014 | Jan 5, 2015 | 25 | United States |
| Arm | Type | Description |
|---|---|---|
| 3 μg ACC-001 / QS-21 50 μg IM dose 1 | EXPERIMENTAL | 3 μg ACC-001 / QS-21 50 μg IM |
| 10 μg ACC-001 / QS-21 50 μg IM dose 2 | EXPERIMENTAL | 10 μg ACC-001 / QS-21 50 μg IM |
| Placebo - Phosphate buffered saline (PBS) IM dose | NO_INTERVENTION | Placebo - Phosphate buffered saline (PBS) IM |
| Name | Type | Description |
|---|---|---|
| ACC-001 (vanutide cridificar) | BIOLOGICAL | Comparisons of 2 different doses of ACC-001 or placebo for 24 months |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiver able to...